Y.B Urban Renewal - Residential Development LTD
CSURE-M | TA
Overview
Corporate Details
- ISIN(s):
- IL0001110134
- LEI:
- Country:
- Israel
- Address:
- 2 Hahadarim Street, 7712102 Ashdod
- Website:
- https://www.yb-i.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cannassure-M focuses on the development and production of medical cannabis products in Israel.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-15 19:43 |
Regulatory Filings
Trading in the company's shares (ISIN IL0001110134) will be renewed on Monday, …
|
Hebrew (modern) | 113.5 KB | ||
| 2025-05-05 15:53 |
Regulatory Filings
The securities not included in the Illiquid list as of May 4th
2025 due to mar…
|
Hebrew (modern) | 217.1 KB | ||
| 2025-05-05 11:32 |
Regulatory Filings
Suspension of trading due to failure in publication of financial reports s for …
|
Hebrew (modern) | 79.7 KB | ||
| 2025-04-28 18:40 |
Regulatory Filings
Securities that have joined the program and the Market Makers that will operate…
|
Hebrew (modern) | 366.8 KB | ||
| 2025-04-20 18:21 |
Regulatory Filings
Failure in publishing financial reports-Notification
|
Hebrew (modern) | 128.0 KB | ||
| 2025-03-06 18:39 |
Regulatory Filings
Illiquid Candidates securities list as of May 4th 2025
|
Hebrew (modern) | 245.6 KB | ||
| 2024-07-28 18:05 |
Regulatory Filings
The company's securities will be transferred from the maintenance list to the m…
|
Hebrew (modern) | 106.5 KB | ||
| 2024-07-11 17:14 |
Regulatory Filings
Changes in the company's share symbol correction: YBRD-M
|
Hebrew (modern) | 104.0 KB | ||
| 2024-07-09 17:01 |
Regulatory Filings
Changes in the company's name and security, effective as of July 11, 2024
|
Hebrew (modern) | 105.9 KB | ||
| 2024-06-25 19:48 |
Regulatory Filings
Changes in Sector Classification of Listed Companies as of Sunday, June 30, 2024
|
Hebrew (modern) | 135.9 KB | ||
| 2024-03-21 18:45 |
Regulatory Filings
Will trade on Monday March 25 2024, with unlimited price fluctuation at the ope…
|
Hebrew (modern) | 137.2 KB | ||
| 2023-07-13 20:43 |
Regulatory Filings
Transfer to the Maintenance List on July 17, 2023
|
Hebrew (modern) | 149.7 KB | ||
| 2023-07-03 19:48 |
Regulatory Filings
Companies that do not comply with the Maintenance Rules and are candidates to b…
|
Hebrew (modern) | 116.3 KB | ||
| 2023-01-15 17:37 |
Regulatory Filings
Non-Compliance with the Maintenance Rules Based on Data as of December 31, 2022…
|
Hebrew (modern) | 132.9 KB | ||
| 2021-01-07 15:45 |
Regulatory Filings
On Sunday, 10 January 2021, trading will commence in the following Security: CA…
|
Hebrew (modern) | 186.1 KB |
Automate Your Workflow. Get a real-time feed of all Y.B Urban Renewal - Residential Development LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Y.B Urban Renewal - Residential Development LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Y.B Urban Renewal - Residential Development LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
United States of America
AIM
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
United States of America
AKAN
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
United States of America
AKTX
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
United States of America
AKBA
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
United States of America
AKRO
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
United States of America
TCRT
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
United States of America
ALDX
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
United States of America
ALEC
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
United States of America
ALGS
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK
Denmark
ALK